QRxPharma Granted US Patent On Hybrid Opioids

                QRxPharma Granted US Patent On Hybrid Opioids

Composition of Matter Patent Provides Coverage Until 2031

PR Newswire

SYDNEY and BEDMINSTER, N.J., June 12, 2013

SYDNEY and BEDMINSTER, N.J., June 12, 2013 /PRNewswire/ --QRxPharma
Limited(ASX: QRX and OTCQX: QRXPY) announced today that the United States
Patent and Trademark Office (USPTO) issued the Company U.S. Patent #8,461,171
("'171 patent") titled "Hybrid Opioid Compounds and Compositions," which
expires in 2031. This patent covers a hybridmorphine-oxycodone molecule
where these two different opioids arechemically linked.The '171 patent
covers the development of newchemical entities that have the potential to
provide better pain relief and fewer side effects than their individual
components. The Company hasrelated patents pending both internationally and
in the United States.

"This patent expands our intellectual property (IP) position and protects next
generation Dual-Opioid^® combinationproducts that are chemically unique,"
said Dr. John Holaday, Managing Director and Chief Executive Officer.
"Further, issuance of this patent enhances our long-term marketexclusivity
for QRxPharma's Dual-Opioid^® products for thetreatment of acute and chronic

Immediate release MOXDUO^® is a combination of two separate opioid salts
inthe same capsule, and is presently under review at the USFood and Drug
Administration for the treatment of moderate to severe acute pain. By
contrast, this newly issued patent covers different opioid combinations that
when linked together offer a new composition of matter having activity that is
greater than equimolar amounts of the molecules administered separately.

About QRxPharma
QRxPharma Limited is an Australian based, commercial-stage specialty
pharmaceutical company focused on the development and commercialisation of new
treatments for pain management. The Company's product portfolio includes both
late and early stage clinical drug candidates with the potential for reduced
risk, abbreviated development paths, and improved patient outcomes. The
Company's lead product candidate, immediate release MOXDUO^® for the treatment
of acute pain, is presently under review at the US Food and Drug
Administration. QRxPharma entered into strategic collaborations with Actavis
Inc. in December 2011 and Paladin Labs Inc. in October 2012 for the
commercialisation of immediate release MOXDUO^® in the US and Canadian acute
pain markets respectively. Additionally, the Company's clinical pipeline
includes an intravenous (IV) and continuous release (CR) formulation of
MOXDUO. For more information, visit www.qrxpharma.com.

Forward Looking Statements
This release contains forward-looking statements. Forward-looking statements
are statements that are not historical facts; they include statements about
our beliefs and expectations. Any statement in this release that states our
intentions, beliefs, expectations or predictions (and the assumptions
underlying them) is a forward-looking statement. These statements are based on
plans, estimates and projections as they are currently available to the
management of QRxPharma. Forward-looking statements therefore speak only as of
the date they are made, and we undertake no obligation to update publicly any
of them in light of new information or future events. By their very nature,
forward-looking statements involve risks and uncertainties. A number of
important factors could therefore cause actual results to differ materially
from those contained in any forward-looking statement. Such factors include
risks relating to the stage of products under development; uncertainties
relating to clinical trials; dependence on third parties; future capital
needs; and risks relating to the commercialisation of the Company's proposed

SOURCE QRxPharma Limited

Website: http://qrxpharma.com/
Press spacebar to pause and continue. Press esc to stop.